Pulmonary hypertension is a serious and often life-threatening condition in which high blood pressure occurs in the arteries of the lungs. This can lead to shortness of breath, fatigue, and chest pain, among other symptoms.

While there is no cure for pulmonary hypertension, there is hope for patients with this condition thanks to recent FDA approvals of two new treatments from pharmaceutical company Bayer.

Understanding Pulmonary hypertension

Pulmonary hypertension is a rare but serious condition that affects the heart and lungs. It is characterized by high blood pressure in the arteries of the lungs, which makes it difficult for the heart to pump blood through the lungs.

This can cause a range of symptoms, including shortness of breath, fatigue, chest pain, and swelling in the legs and ankles.

Pulmonary hypertension can be caused by a number of factors, including genetics, some types of medications, and exposure to certain chemicals or toxins.

It can also be associated with underlying conditions such as heart disease, lung disease, or blood clots.

The Importance of Treatment for Pulmonary Hypertension

Pulmonary hypertension is a serious and potentially life-threatening condition. If left untreated, it can cause significant damage to the heart and lungs, which can lead to heart failure and other complications.

However, with proper treatment, many patients are able to manage their symptoms and live longer, healthier lives.

The Role of Bayer in Treating Pulmonary Hypertension

Bayer is a pharmaceutical company that is dedicated to developing innovative treatments for a range of conditions, including pulmonary hypertension. The company has recently received FDA approval for two new treatments for this condition.

Related Article Bayer gets FDA approval for two types of Pulmonary Hypertension

Riociguat (Adempas)

Riociguat is a medication that is used to treat pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

It works by relaxing the blood vessels in the lungs, which allows blood to flow more easily and reduces the strain on the heart.

Riociguat has been shown to be effective in reducing symptoms and improving exercise capacity in patients with PAH and CTEPH. It is taken orally, usually three times a day, and can be prescribed by a doctor.

Vardenafil (Levitra)

Vardenafil is a medication that is used to treat erectile dysfunction (ED) in men. However, it has also been found to be useful in treating pulmonary hypertension in some cases.

Vardenafil works by relaxing the blood vessels in the lungs, which allows blood to flow more easily and reduces the strain on the heart.

While vardenafil is not currently approved by the FDA for the treatment of pulmonary hypertension, some doctors may prescribe it off-label for this purpose. Patients should always talk to their doctors before taking any new medications.

Conclusion

Pulmonary hypertension is a serious condition that requires proper treatment and management. With the recent FDA approvals of two new treatments from Bayer, patients with this condition have reason to be hopeful.

Riociguat and vardenafil are both medications that have been shown to be effective in reducing symptoms and improving exercise capacity in patients with pulmonary hypertension. As always, patients should work closely with their doctors to find the best course of treatment for their individual needs.